NEW ORLEANS (April 29, 2021) The Commission on Cancer (CoC), a quality program of the American College of Surgeons (ACS) has granted Three-Year Accreditation to the cancer program at Touro. To earn voluntary CoC accreditation, a cancer program must meet 34 CoC quality care standards, be evaluated every three years through a survey process, and maintain levels of excellence in the delivery of comprehensive patient-centered care. This is the 48th year Touro has been accredited with the Commission on Cancer since first receiving the designation in 1973.
Because it is a CoC-accredited cancer center, Touro takes a multidisciplinary approach to treating cancer as a complex group of diseases that requires consultation among surgeons, medical and radiation oncologists, diagnostic radiologists, pathologists, and other cancer specialists. This multidisciplinary partnership results in improved patient care.
“We are pleased to once again receive this prestigious accreditation from the American College of Surgeons highlighting our commitment to excellence in cancer care,” explains Manny Linares, President and CEO of Touro. “Our multidisciplinary team’s collaborative approach to cancer care has not only led to successful treatment plans and journeys to survivorship for our patients, but has made Touro a destination for comprehensive, quality cancer care.”
The CoC Accreditation Program provides the framework for Touro to improve its quality of patient care through various cancer-related programs that focus on the full spectrum of cancer care including prevention, early diagnosis, cancer staging, optimal treatment, rehabilitation, life-long follow-up for recurrent disease, and end-of-life care. When patients receive care at a CoC facility, they also have access to information on clinical trials and new treatments, genetic counseling, and patient-centered services including psycho-social support, a patient navigation process, and a survivorship care plan that documents the care each patient receives and seeks to improve cancer survivors’ quality of life.
Like all CoC-accredited facilities, Touro maintains a cancer registry and contributes data to the National Cancer Data Base (NCDB), a joint program of the CoC and American Cancer Society. This nationwide oncology outcomes database is the largest clinical disease registry in the world. Data on all types of cancer are tracked and analyzed through the NCDB and used to explore trends in cancer care. CoC-accredited cancer centers, in turn, have access to information derived from this type of data analysis, which is used to create national, regional, and state benchmark reports. These reports help CoC facilities with their quality improvement efforts.
The American Cancer Society estimates that more than 1.7 million cases of cancer will be diagnosed in 2018. There are currently more than 1,500 CoC-accredited cancer programs in the U.S. and Puerto Rico, CoC-accredited facilities diagnose and/or treat more than 70 percent of all newly diagnosed patients with cancer. When cancer patients choose to seek care locally at a CoC-accredited cancer center, they are gaining access to comprehensive, state-of-the-art cancer care close to home. The CoC provides the public with information on the resources, services, and cancer treatment experience for each CoC-accredited cancer program through the CoC Hospital Locator at https://www.facs.org/search/cancer-programs.
Established in 1922 by the American College of Surgeons, the CoC is a consortium of professional organizations dedicated to improving patient outcomes and quality of life for cancer patients through standard-setting, prevention, research, education, and the monitoring of comprehensive, quality care. Its membership includes Fellows of the American College of Surgeons. For more information, visit: www.facs.org/cancer